Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for treatment of non-affective psychosis and cannabis use
2024-517630-18-00Phase 3Completed
- Sponsor
- Capital Region of Denmark
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, brief psychotic disorder (BPD), schizoaffective disorder and 3 more comparing Epidyolex + risperidone with Epidyolex placebo + risperidone (2 arms). Primary endpoint: Severity of psychotic symptoms. Started Oct 2024; status: completed.
02
Drugs
cannabidiol
03
Conditions
schizophreniabrief psychotic disorder (BPD)schizoaffective disorderUnspecified psychosiscannabis-induced psychosis (CIPD)
Beyond the preview
Go deeper on 2024-517630-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517630-18-00.